Oxford Biomedica and Beam Therapeutics sign CAR-T deal
Agreement will utilise Oxford Biomedica’s LentiVector platform
Read More
Tag: Beam Therapeutics
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
